Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 January 2021 | Story Leonie Bolleurs | Photo Supplied
Dr Anamika Megwalu, an assessment and engineering librarian at San Jose State University in California in the United States (US), addressed a group of staff from the UFS Department of Library and Information Services.

Dr Anamika Megwalu, an assessment and engineering librarian at San Jose State University in California in the United States (US), pointed out that building a lasting and sustainable relationship with departments and upholding quality in the library environment is key. 

She addressed a group of colleagues from our Department of Library and Information Services (LIS) on 25 November 2020.

Tight budgets call for proper assessment

Her presentation, titled Library Collection Development, was aimed at sharing her experience of working in the collection development and liaison sections within the LIS ecosystem. 

“This librarian-cum-computer science lecturer has the benefit of both worlds, having worked in private and public academic libraries such as Stafford University and City University of New York respectively,” says Monde Madiba, Deputy Director: Collection Development and Management of LIS at the University of the Free State.

San Jose, the oldest public university in the western US, is located in the heart of Silicon Valley, serving more than 33 000 students enrolled in 10 colleges and 67 departments.

According to Dr Megwalu, the tight budgets that public academic libraries such as San Jose receive, call for proper assessment of library collections in order to deal with the constraints. She emphasised the need to “uphold quality within the constraints”.

Moving from collecting information to creating information

Some of the ideas that Dr Megwalu shared for conducting assessment and collection development, includes the following:
• Change the library’s image from being a collector of information to being the creator of information.
• Consider the size of the different departments: some may need little or no attention due to size, while others may need close attention due to intensive research by lecturers within the department.
• Identify gaps and focus your attention on filling them with the relevant collection.
• Make sure that you are aware of the accreditation period of different programmes, since the role that academic libraries play in collection development is recognised by such agencies.
• Build a lasting and sustainable relationship with departments. This includes knowing the lecturers’ research interests, assisting the newly established departments, attending free webinars, and participating in student activities.
• Ensure equal distribution of the budget and ensure that everyone has equal access to it.
• Create a timetable where everyone knows when to submit requests for prescribed books. Make it clear that it takes approximately three weeks on average for ordered books to be delivered.
• Develop department-specific collection development policies.
• Be ready to move with the times, e.g. replace DVDs in favour of video-streaming services.
• Shift towards a 100% electronic reference collection.
• Consider having an electronic version for popular but currently in-print collections.
• Develop an indigenous collection based on the contributions of communities around the university.
• Create a portal for open educational resources (OERs) from participating institutions across the globe.

“Dr Megwalu’s presentation was not only informative but a testimony that collection development and assessment are dynamic and driven by passion and love,” says Madiba.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept